Publication | Closed Access

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ph Iii StudyHepatologyMedicinePathologyPharmacotherapySafety ResultsLiver CancerCancer TreatmentVs SorafenibOncologyRadiation OncologyHepatocellular CarcinomaMolecular Oncology